Compare EBF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBF | ALT |
|---|---|---|
| Founded | 1909 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.5M | 421.5M |
| IPO Year | 1994 | 2005 |
| Metric | EBF | ALT |
|---|---|---|
| Price | $21.98 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 111.6K | ★ 3.8M |
| Earning Date | 04-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | 7.79 | ★ 25.37 |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $55.90 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $16.30 | $2.56 |
| 52 Week High | $22.36 | $6.44 |
| Indicator | EBF | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 53.21 |
| Support Level | $19.92 | $2.65 |
| Resistance Level | $22.36 | $3.15 |
| Average True Range (ATR) | 0.37 | 0.17 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 74.58 | 41.07 |
Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others. The company's single reportable segment : Print derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.